SCHEMBL4506540

SCHEMBL4506540

Cc1c(F)cccc1N(c1cccc(F)c1C)S(=O)(=O)c1cc(S(N)(=O)=O)cc2ccc(O)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.40
MCL1 Q07820 1/20 0.35
ESR1 P03372 4/20 0.34
ESR2 Q92731 3/20 0.34
HSD17B1 P14061 3/20 0.33
HSD17B2 P37059 3/20 0.33
RAB9A P51151 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
CA2 P00918 2/20 0.32
GLO1 Q04760 1/20 0.31
LOXL2 Q9Y4K0 2/20 0.31
NPC1 O15118 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA9 Q16790 1/20 0.31
STS P08842 1/20 0.31
MPL P40238 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4508410 0.88 PTGES (0.41) PTGESMCL1ESR1RAB9AKDM4E
SCHEMBL4503637 0.87 PTGES (0.40) PTGESMCL1ESR1MEN1KMT2A
SCHEMBL4505853 0.84 PTGES (0.46) PTGESMCL1ESR1ESR2HSD17B1
SCHEMBL4511441 0.83 PTGES (0.40) PTGESMCL1ESR1RAB9ACA2
SCHEMBL4497549 0.83 PTGES (0.35) PTGESMCL1ESR1CA2GLO1
SCHEMBL4497864 0.82 ESR1 (0.42) PTGESESR1HSD17B1HSD17B2RAB9A
SCHEMBL4500899 0.81 PTGES (0.46) PTGESMCL1ESR1ESR2HSD17B1
SCHEMBL4503529 0.81 ESR1 (0.41) PTGESMCL1ESR1RAB9ACA2
SCHEMBL4510732 0.81 PTGES2 (0.41) PTGESMCL1ESR1ESR2CA2
SCHEMBL4510070 0.81 PTGES (0.39) PTGESMCL1ESR1ESR2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090234014-A1 Naphthalene-Disulfonamides Useful for the Treatment of Inflammation BIOLIPOX AB (SE) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234014-A1 Naphthalene-Disulfonamides Useful for the Treatment of Inflammation AREG, PRSS12, CXCL8 PTGES 41/4885MCL1 696/4885ESR1 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.